Abstract
The USFDA is an agency of the US Department of Health and Human Services and is the nation’s oldest consumer protection agency whose function it is to review drugs before marketing, monitor marketed drugs, monitor drug manufacturing and advertising, protect drug quality, and to conduct applied research. It is charged with overseeing of not only human drugs and biologics, but also veterinary drugs, foods, medical devices, and radiopharmaceuticals, and as such serves as a watch dog over industry. This chapter discusses the historical development of the FDA, and what the FDA is today. The phases of research development leading to the marketing of a new drug, the role of the FDA in surgical interventions, and the FDA’s role in advertising and adverse event reporting are discussed.
Preview
Unable to display preview. Download preview PDF.
References
Lewis S, Baird P, Evans RG, et al. Dancing with the porcupine: rules for governing the university-industry relationship. CMAJ. Sept 18, 2001; 165(6):783–785.
The Historical Guide to American Government. New York: Oxford Press; 1998.
Swann R. History of the FDA. www.fda.gov/oc/history. Accessed May 9, 2007.
Guidance for Industry. www.fda.gov/cber/guidelines.
Thelithromycin. Wikipedia.
FDA Amendment Act of 2007; 2007.
The Mission Statement of the ICH. http://www.ich.org/
Coronary Drug Project. www.fda.gov
Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. Sept 7, 2006; 355(10):1018–1028.
European Medicines Agency (EMEA). http.www.emea.europa.
O’Donnell P. Not yet the last word on first-in-man. Appl Clin Trials. 2007; 16:34–38.
Palesch YY, Tilley BC, Sackett DL, Johnston KC, Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke. Nov 2005; 36(11):2410–2414.
Henderson L. The long arm of the FDA. Appl Clin Trials. 2007.
Ramsey SD, Sullivan SD. Evidence, economics, and emphysema: medicare’s long journey with lung volume reduction surgery. Health Aff (Millwood). Jan–Feb 2005; 24(1):55–66.
Brantigan OC, Mueller E. Surgical treatment of pulmonary emphysema. Am Surg. Sept 1957; 23(9):789–804.
Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. Jan 1995; 109(1): 106–116; discussion 116–109.
Tunis SR, Pearson SD. Coverage options for promising technologies: medicare’s ‘coverage with evidence development’. Health Aff (Millwood). Sept–Oct 2006; 25(5):1218–1230.
Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. May 22, 2003; 348(21):2059–2073.
Kolata G. Medicare says it will pay, but patients say ‘no thanks’. New York Times. March 3, 2006, 2006; C:1.
Al-Naaman YD, Carton CA, Cooley DA. Surgical treatment of arteriosclerotic occlusion of common carotid artery. J Neurosurg. Sept 1956; 13(5):500–506.
Winslow CM, Solomon DH, Chassin MR, Kosecoff J, Merrick NJ, Brook RH. The appropriateness of carotid endarterectomy. N Engl J Med. Mar 24, 1988; 318(12):721–727.
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. Aug 15, 1991; 325(7):445–453.
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. May 10, 1995; 273(18):1421–1428.
Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. Nov 12, 1998; 339(20):1415–1425.
Halm EA, Tuhrim S, Wang JJ, Rojas M, Hannan EL, Chassin MR. Has evidence changed practice?: appropriateness of carotid endarterectomy after the clinical trials. Neurology. Jan 16, 2007; 68(3):187–194.
Moseley JB, O’Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. July 11, 2002; 347(2):81–88.
Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. JAMA. Nov 22, 2006; 296(20):2441–2450.
Horng S, Miller FG. Ethical framework for the use of sham procedures in clinical trials. Crit Care Med. Mar 2003; 31(3 Suppl):S126–130.
Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med. Sept 23, 1999; 341(13):992–996.
Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. Mar 8, 2001; 344(10):710–719.
Brody BA. The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press; 1998.
Wennberg JE. An apple a day? N Engl J Med. Sept 22, 1994, 1994; 331(12):815–816.
FDA Website. 6/10/07; http://www.fda.gov/opacom/morechoices/mission.html
Division of Drug Marketing, Advertising, and Communications, Food and Drug Administration. 5/31/07; http://www.fda.gov/cder/ddmac
21 CFR Part 310 section 502(a) of the Food and Drug Administration Modernization Act of 1997. In: Department of Health and Human Services FaDA, ed. Vol 21 U.S.C. 352(a).
Baylor-Henry M, Drezin N. Regulation of prescription drug promotion: direct-to consumer advertising. Clin Ther. 1998; 20(C):C86–C95.
Section 502(n) of the Food Drug and Cosmetics Act, and Title 21 Code of Federal Regulations. Vol 202.1(1)(1).
Kessler DA, Pines WL. The federal regulation of prescription drug advertising and promotion. JAMA. Nov 14, 1990; 264(18):2409–2415.
21 CFR Part 310 section 502(a) of the Food and Drug Administration Modernization Act of 1997 (Modernization Act).. In: Department of Health and Human Services FaDA, ed. Vol 21 U.S.C. 352 (n).
Section 502(n) of the Food Drug and Cosmetics Act, and Title 21 Code of Federal Regulations. Vol 202.1(j)(1).
Section 502 (n) of the Food Drug and Cosmetics Act, and Title 21 Code of Federal Regulations. Vol 202.1.
21 CFR Part 310 section 502(a) of the Food and Drug Administration Modernization Act of 1997 (Modernization Act). Vol 21 314.81(b)(3).
Woodcock J. Statement by Janet Woodcock, MSD Director, Center of Drug Evaluation and Research. US Drug Administration. Rockville, MD: Department of Health and Human Services; 2003.
Gahart MT, Duhamel LM, Dievler A, Price R. Examining the FDA’s oversight of direct to consumer advertising. Health Affairs. 2003; W3:120–123.
Waxman HA. Ensuring that consumers receive appropriate information from drug ads: what is the FDA’s role? Health Affairs. 2004; W4:256–258.
Waxman RHA. Letter from Rep. Henry A. Waxman to the Honorable Tommy G. Thompson. http://oversight.house.gov/story.asp?ID=441. Accessed June 1, 2007.
Food and Drug Administration. http://www.fda.gov/opacom/backgrounders/miles.html. Accessed October 6, 2007.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Glasser, S.P., Ashton, C.M., Wray, N.P. (2008). The United States Federal Drug Administration (FDA) and Clinical Research. In: Glasser, S.P. (eds) Essentials of Clinical Research. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8486-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8486-7_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8485-0
Online ISBN: 978-1-4020-8486-7
eBook Packages: MedicineMedicine (R0)